SENS
$6.49
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
Intraday
Recent News
Senseonics Reports Strong One-Year Real-World Data for Eversense 365
SENS highlights strong one-year real-world data for Eversense 365, reinforcing adherence, glucose control and long-term adoption potential.
Wall Street Analysts Predict a 124.49% Upside in Senseonics (SENS): Here's What You Should Know
The consensus price target hints at a 124.5% upside potential for Senseonics (SENS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Senseonics Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Senseonics Holdings, Inc.'s Q4 2025 earnings call
Senseonics Holdings Inc (SENS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Despite a net loss, Senseonics Holdings Inc (SENS) reports significant revenue growth and strategic advancements in product approvals and market expansions.
Senseonics Holdings, Inc. Common Stock Q4 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) reported fourth-quarter and full-year 2025 results highlighted by the U.S. ramp of its Eversense 365 continuous glucose monitor (CGM), a major shift in commercial strategy, and an updated 2026 outlook that reflects the company’s move to bring sale